DBV Technologies S.A. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by DBV Technologies S.A. on June 3, 2026. The filing details the approval and grant of the DBV Technologies 2026 Performance Share Unit Plan to Daniel Tassé, the Company's Chief Executive Officer. The grant date is June 5, 2026, authorized by the Board of Directors following shareholder approval at the Annual General Meeting held on June 3, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial statement data.
Material Changes and Executive Compensation
The primary material event is the grant of 4,060,000 Performance Share Units (PSUs) to the CEO. The vesting of these units is contingent upon specific regulatory milestones and continued employment:
- First Performance Condition: 2,900,000 PSUs vest upon the first FDA approval of a Biologics License Application (BLA) for Viaskin Peanut (VP), regardless of the age group.
- Second Performance Condition: 1,160,000 PSUs vest upon a second FDA approval of a VP BLA for a different indication or age group.
- Single Approval Scenario: If a single BLA covers both age groups, all PSUs become eligible to vest.
- Forfeiture: Unvested PSUs are automatically cancelled if conditions are not met by July 1, 2028.
- Delivery Schedule: Vested shares are delivered in four 25% installments on July 1, 2028; January 1, 2029; July 1, 2029; and January 1, 2030.
Outlook, Risks, and Contingencies
The compensation plan aligns executive incentives with the regulatory success of the Company's lead product, Viaskin Peanut. Key contingencies include:
- Continued Employment: Vesting requires the CEO to remain employed continuously until the vesting date, with exceptions for death, disability, qualifying retirement, or termination without cause/for good reason.
- Change in Control: In the event of a Change in Control, all performance conditions are deemed achieved, though the continued employment condition and delivery schedule generally remain in effect.
- Tax Considerations: The Board may substitute cash for shares if the CEO is not a French tax resident at delivery. Section 409A of the U.S. Internal Revenue Code may defer payments for specified employees by six months following separation from service.
Investor Verification Checklist
- Verify the full text of the 2026 Performance Share Unit Plan filed as Exhibit 10.1.
- Monitor FDA regulatory filings and decisions regarding Viaskin Peanut BLAs to assess vesting probability.
- Review the Company's cash position to evaluate the potential impact of cash substitutions for share delivery if tax residency changes.
- Confirm the CEO's continued employment status through the July 1, 2028 vesting date.